Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

SGLT inhibitors: a novel target for diabetes.

Kanwal A, Banerjee SK.

Pharm Pat Anal. 2013 Jan;2(1):77-91. doi: 10.4155/ppa.12.78. Review.

PMID:
24236972
2.

Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.

Zambrowicz B, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Boehm KA, Ruff D, Powell D, Sands A.

Clin Ther. 2013 Aug;35(8):1162-1173.e8. doi: 10.1016/j.clinthera.2013.06.011. Epub 2013 Jul 31.

PMID:
23911260
3.

Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.

Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Smith M, Ruff D, Sands A, Powell D.

Clin Ther. 2013 Mar;35(3):273-285.e7. doi: 10.1016/j.clinthera.2013.01.010. Epub 2013 Feb 21.

PMID:
23433601
4.

LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.

Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, Mseeh F, Shadoan MK, Sands A, Zambrowicz B, Ding ZM.

J Pharmacol Exp Ther. 2013 May;345(2):250-9. doi: 10.1124/jpet.113.203364. Epub 2013 Mar 13.

5.

Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG.

Chang HC, Yang SF, Huang CC, Lin TS, Liang PH, Lin CJ, Hsu LC.

Mol Biosyst. 2013 Aug;9(8):2010-20. doi: 10.1039/c3mb70060g. Epub 2013 May 8.

PMID:
23657801
6.

Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy.

Lapuerta P, Rosenstock J, Zambrowicz B, Powell DR, Ogbaa I, Freiman J, Cefalu WT, Banks P, Frazier K, Kelly M, Sands A.

Clin Cardiol. 2013 Jul;36(7):367-71. doi: 10.1002/clc.22125. Epub 2013 Apr 29.

7.

Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2.

Kanwal A, Singh SP, Grover P, Banerjee SK.

Anal Biochem. 2012 Oct 1;429(1):70-5. doi: 10.1016/j.ab.2012.07.003. Epub 2012 Jul 14.

PMID:
22796500
8.

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.

Lapuerta P, Zambrowicz B, Strumph P, Sands A.

Diab Vasc Dis Res. 2015 Mar;12(2):101-10. doi: 10.1177/1479164114563304. Review.

PMID:
25690134
9.

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.

Nagata T, Fukazawa M, Honda K, Yata T, Kawai M, Yamane M, Murao N, Yamaguchi K, Kato M, Mitsui T, Suzuki Y, Ikeda S, Kawabe Y.

Am J Physiol Endocrinol Metab. 2013 Feb 15;304(4):E414-23. doi: 10.1152/ajpendo.00545.2012. Epub 2012 Dec 18.

PMID:
23249697
10.

Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.

Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, Ueta K, Shiotani M, Nagamori S, Kanai Y.

J Pharmacol Exp Ther. 2016 Jul;358(1):94-102. doi: 10.1124/jpet.116.232025. Epub 2016 Apr 27.

11.

[Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].

Wan HX, Shen JK.

Yao Xue Xue Bao. 2012 Jun;47(6):716-24. Review. Chinese.

PMID:
22919717
12.

Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.

Song P, Onishi A, Koepsell H, Vallon V.

Expert Opin Ther Targets. 2016 Sep;20(9):1109-25. doi: 10.1517/14728222.2016.1168808. Epub 2016 Apr 12. Review.

13.

The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer.

Koepsell H.

Pharmacol Ther. 2017 Feb;170:148-165. doi: 10.1016/j.pharmthera.2016.10.017. Epub 2016 Oct 20. Review.

PMID:
27773781
14.

In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach.

Yamaguchi K, Kato M, Suzuki M, Hagita H, Takada M, Ayabe M, Aso Y, Ishigai M, Ikeda S.

J Pharmacol Exp Ther. 2013 Apr;345(1):52-61. doi: 10.1124/jpet.113.203125. Epub 2013 Feb 5.

15.

Sotagliflozin as a potential treatment for type 2 diabetes mellitus.

Cariou B, Charbonnel B.

Expert Opin Investig Drugs. 2015;24(12):1647-56. doi: 10.1517/13543784.2015.1100361. Epub 2015 Nov 7. Review.

PMID:
26548423
16.

Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?

Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, Pollock C, Mather A.

PLoS One. 2013;8(2):e54442. doi: 10.1371/journal.pone.0054442. Epub 2013 Feb 4.

17.

Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1,2,3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors.

Putapatri SR, Kanwal A, Banerjee SK, Kantevari S.

Bioorg Med Chem Lett. 2014 Mar 15;24(6):1528-31. doi: 10.1016/j.bmcl.2014.01.077. Epub 2014 Feb 6.

PMID:
24556379
18.

Sodium-glucose transporter 2 inhibitors in type 2 diabetes mellitus: navigating between Scylla and Charybdis.

Machado UF, CorrĂȘa-Giannella ML.

Expert Opin Emerg Drugs. 2014 Mar;19(1):5-9. doi: 10.1517/14728214.2014.875530. Epub 2014 Jan 8.

PMID:
24397354
19.

Effect of LX4211 on glucose homeostasis and body composition in preclinical models.

Powell DR, DaCosta CM, Smith M, Doree D, Harris A, Buhring L, Heydorn W, Nouraldeen A, Xiong W, Yalamanchili P, Mseeh F, Wilson A, Shadoan M, Zambrowicz B, Ding ZM.

J Pharmacol Exp Ther. 2014 Aug;350(2):232-42. doi: 10.1124/jpet.114.214304. Epub 2014 May 21.

20.

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.

Oguma T, Kuriyama C, Nakayama K, Matsushita Y, Yoshida K, Kiuchi S, Ikenaga Y, Nakamaru Y, Hikida K, Saito A, Arakawa K, Oka K, Ueta K, Shiotani M.

J Pharmacol Sci. 2015 Apr;127(4):456-61. doi: 10.1016/j.jphs.2015.03.006. Epub 2015 Mar 28.

Supplemental Content

Support Center